Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Drug Eruptions | 12 | 2024 | 335 | 4.460 |
Why?
|
Skin Diseases | 14 | 2024 | 1088 | 4.000 |
Why?
|
Pemphigoid, Bullous | 6 | 2024 | 109 | 3.560 |
Why?
|
Exanthema | 10 | 2024 | 502 | 3.200 |
Why?
|
Stevens-Johnson Syndrome | 7 | 2024 | 231 | 3.070 |
Why?
|
Skin | 21 | 2024 | 4489 | 2.680 |
Why?
|
Neoplasms | 26 | 2025 | 22340 | 1.810 |
Why?
|
Dermatology | 13 | 2023 | 907 | 1.770 |
Why?
|
Immunotherapy | 16 | 2023 | 4752 | 1.420 |
Why?
|
Skin Neoplasms | 10 | 2024 | 5849 | 1.160 |
Why?
|
Administration, Cutaneous | 7 | 2023 | 715 | 1.040 |
Why?
|
Melanoma | 8 | 2023 | 5719 | 0.980 |
Why?
|
Pemphigoid Gestationis | 1 | 2024 | 4 | 0.950 |
Why?
|
Mycosis Fungoides | 3 | 2021 | 155 | 0.940 |
Why?
|
Xylazine | 1 | 2024 | 12 | 0.910 |
Why?
|
Colitis | 3 | 2020 | 1239 | 0.830 |
Why?
|
Vasculitis, Leukocytoclastic, Cutaneous | 1 | 2023 | 43 | 0.810 |
Why?
|
Skin Ulcer | 1 | 2024 | 130 | 0.810 |
Why?
|
Immunosuppressive Agents | 3 | 2024 | 4209 | 0.730 |
Why?
|
Professional Autonomy | 2 | 2019 | 172 | 0.680 |
Why?
|
Macrophages, Alveolar | 1 | 2022 | 413 | 0.670 |
Why?
|
Pemphigus | 1 | 2021 | 107 | 0.670 |
Why?
|
Lymphoma, Follicular | 1 | 2024 | 459 | 0.670 |
Why?
|
Necrosis | 1 | 2024 | 1617 | 0.650 |
Why?
|
Skin Diseases, Vesiculobullous | 1 | 2020 | 84 | 0.640 |
Why?
|
Substance Abuse, Intravenous | 1 | 2024 | 531 | 0.640 |
Why?
|
Tuberculosis, Cutaneous | 1 | 2019 | 17 | 0.640 |
Why?
|
Cryoglobulinemia | 1 | 2019 | 83 | 0.610 |
Why?
|
Vasculitis | 1 | 2023 | 527 | 0.610 |
Why?
|
Pemphigus, Benign Familial | 1 | 2018 | 8 | 0.600 |
Why?
|
Adrenal Cortex Hormones | 3 | 2022 | 1880 | 0.570 |
Why?
|
Lymphoma, B-Cell | 1 | 2023 | 943 | 0.540 |
Why?
|
Diuretics | 1 | 2020 | 613 | 0.530 |
Why?
|
Humans | 100 | 2025 | 765968 | 0.530 |
Why?
|
Leg Dermatoses | 1 | 2015 | 20 | 0.500 |
Why?
|
Naltrexone | 1 | 2018 | 319 | 0.490 |
Why?
|
Leg Ulcer | 1 | 2015 | 70 | 0.480 |
Why?
|
Placenta | 1 | 2024 | 1728 | 0.480 |
Why?
|
Anti-Bacterial Agents | 3 | 2024 | 7478 | 0.480 |
Why?
|
Methotrexate | 1 | 2021 | 1722 | 0.470 |
Why?
|
Immune Tolerance | 2 | 2020 | 2324 | 0.440 |
Why?
|
Retrospective Studies | 27 | 2024 | 81514 | 0.430 |
Why?
|
Drug Hypersensitivity | 1 | 2022 | 902 | 0.430 |
Why?
|
Narcotic Antagonists | 1 | 2018 | 590 | 0.420 |
Why?
|
Insurance Coverage | 1 | 2024 | 1944 | 0.410 |
Why?
|
Photochemotherapy | 1 | 2019 | 826 | 0.410 |
Why?
|
Biopsy | 6 | 2024 | 6763 | 0.410 |
Why?
|
Pharmaceutical Preparations | 1 | 2020 | 1084 | 0.390 |
Why?
|
Autoimmune Diseases | 1 | 2023 | 2226 | 0.370 |
Why?
|
Immunologic Factors | 1 | 2020 | 1587 | 0.370 |
Why?
|
Immunocompromised Host | 1 | 2016 | 866 | 0.360 |
Why?
|
Serine Proteinase Inhibitors | 1 | 2012 | 173 | 0.350 |
Why?
|
Practice Guidelines as Topic | 5 | 2020 | 7425 | 0.350 |
Why?
|
Aged | 29 | 2024 | 171117 | 0.350 |
Why?
|
Female | 41 | 2024 | 396112 | 0.330 |
Why?
|
Diet Therapy | 1 | 2010 | 149 | 0.320 |
Why?
|
Patients | 1 | 2015 | 910 | 0.320 |
Why?
|
Middle Aged | 31 | 2024 | 223009 | 0.310 |
Why?
|
Internship and Residency | 5 | 2023 | 5946 | 0.310 |
Why?
|
Hospitalization | 5 | 2024 | 10808 | 0.300 |
Why?
|
Patient Satisfaction | 2 | 2018 | 3475 | 0.300 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2018 | 1434 | 0.290 |
Why?
|
Male | 40 | 2024 | 363698 | 0.290 |
Why?
|
Lymph Nodes | 1 | 2019 | 3454 | 0.280 |
Why?
|
Gastric Bypass | 1 | 2015 | 820 | 0.270 |
Why?
|
Referral and Consultation | 1 | 2019 | 3615 | 0.260 |
Why?
|
Oligopeptides | 1 | 2012 | 1192 | 0.260 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 3 | 2021 | 5389 | 0.260 |
Why?
|
Diagnosis, Differential | 4 | 2024 | 12976 | 0.240 |
Why?
|
Healthcare Disparities | 1 | 2020 | 3413 | 0.240 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2018 | 4044 | 0.230 |
Why?
|
Immunoblastic Lymphadenopathy | 1 | 2024 | 40 | 0.230 |
Why?
|
Psoriasis | 2 | 2023 | 919 | 0.230 |
Why?
|
Amoxicillin-Potassium Clavulanate Combination | 1 | 2024 | 32 | 0.230 |
Why?
|
Radioimmunotherapy | 1 | 2024 | 93 | 0.220 |
Why?
|
Paraparesis, Tropical Spastic | 1 | 2023 | 32 | 0.220 |
Why?
|
Hepatitis C, Chronic | 1 | 2012 | 1032 | 0.220 |
Why?
|
Exudates and Transudates | 1 | 2024 | 173 | 0.220 |
Why?
|
Liver | 1 | 2019 | 7562 | 0.210 |
Why?
|
Adult | 21 | 2024 | 223044 | 0.210 |
Why?
|
Human T-lymphotropic virus 1 | 1 | 2023 | 143 | 0.210 |
Why?
|
Dapsone | 1 | 2023 | 57 | 0.200 |
Why?
|
Perineum | 1 | 2024 | 213 | 0.200 |
Why?
|
Lactate Dehydrogenases | 1 | 2022 | 25 | 0.200 |
Why?
|
Lung Neoplasms | 3 | 2021 | 13451 | 0.190 |
Why?
|
Doxycycline | 1 | 2024 | 349 | 0.190 |
Why?
|
Teaching Rounds | 2 | 2016 | 280 | 0.190 |
Why?
|
Anal Canal | 1 | 2024 | 376 | 0.190 |
Why?
|
Neoplasms, Second Primary | 2 | 2019 | 1050 | 0.190 |
Why?
|
Dendritic Cells | 2 | 2025 | 2747 | 0.180 |
Why?
|
Erythema | 1 | 2023 | 262 | 0.180 |
Why?
|
Antipruritics | 1 | 2020 | 31 | 0.180 |
Why?
|
Cross-Sectional Studies | 5 | 2024 | 26318 | 0.180 |
Why?
|
Granuloma | 1 | 2023 | 327 | 0.180 |
Why?
|
Langerhans Cells | 1 | 2021 | 170 | 0.170 |
Why?
|
Prognosis | 6 | 2021 | 29922 | 0.170 |
Why?
|
Aged, 80 and over | 8 | 2024 | 59489 | 0.160 |
Why?
|
Antiviral Agents | 1 | 2012 | 3050 | 0.160 |
Why?
|
Histiocytosis, Langerhans-Cell | 1 | 2021 | 166 | 0.160 |
Why?
|
Plasma Cells | 1 | 2023 | 591 | 0.160 |
Why?
|
Periodontitis | 1 | 2024 | 576 | 0.160 |
Why?
|
Competency-Based Education | 1 | 2020 | 226 | 0.160 |
Why?
|
Colitis, Microscopic | 1 | 2019 | 72 | 0.150 |
Why?
|
Antibodies, Monoclonal | 4 | 2023 | 9249 | 0.150 |
Why?
|
Coronavirus Infections | 3 | 2020 | 3100 | 0.150 |
Why?
|
Budesonide | 1 | 2019 | 163 | 0.150 |
Why?
|
Pneumonia, Viral | 3 | 2020 | 3223 | 0.150 |
Why?
|
Purpura | 1 | 2019 | 115 | 0.150 |
Why?
|
Abdomen | 1 | 2024 | 1134 | 0.150 |
Why?
|
Tumor Microenvironment | 2 | 2021 | 3946 | 0.140 |
Why?
|
Diabetes Mellitus, Type 2 | 2 | 2024 | 12240 | 0.140 |
Why?
|
Immunity, Mucosal | 1 | 2021 | 498 | 0.140 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2025 | 1624 | 0.140 |
Why?
|
Risk Assessment | 6 | 2021 | 24282 | 0.140 |
Why?
|
Consensus | 2 | 2024 | 3202 | 0.140 |
Why?
|
Polypharmacy | 1 | 2020 | 306 | 0.140 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2023 | 1106 | 0.140 |
Why?
|
Macrophages | 2 | 2022 | 5772 | 0.140 |
Why?
|
Shock, Cardiogenic | 1 | 2022 | 704 | 0.140 |
Why?
|
Outpatient Clinics, Hospital | 1 | 2019 | 394 | 0.130 |
Why?
|
Cyclosporine | 1 | 2019 | 778 | 0.130 |
Why?
|
Delayed Diagnosis | 1 | 2020 | 452 | 0.130 |
Why?
|
Coronary Disease | 1 | 2010 | 5912 | 0.130 |
Why?
|
Social Justice | 1 | 2020 | 485 | 0.130 |
Why?
|
Cholesterol | 1 | 2025 | 2898 | 0.130 |
Why?
|
Fibrosis | 1 | 2023 | 2070 | 0.120 |
Why?
|
Ligands | 1 | 2022 | 3273 | 0.120 |
Why?
|
Pain | 2 | 2024 | 5077 | 0.120 |
Why?
|
Sex Distribution | 2 | 2019 | 2263 | 0.120 |
Why?
|
Lymphoproliferative Disorders | 1 | 2019 | 526 | 0.120 |
Why?
|
Survival Rate | 2 | 2019 | 12795 | 0.120 |
Why?
|
Edema | 1 | 2019 | 760 | 0.120 |
Why?
|
Cohort Studies | 8 | 2023 | 41649 | 0.120 |
Why?
|
Biological Specimen Banks | 1 | 2020 | 786 | 0.120 |
Why?
|
Proportional Hazards Models | 3 | 2018 | 12509 | 0.110 |
Why?
|
Respiratory Insufficiency | 1 | 2023 | 1240 | 0.110 |
Why?
|
Communicable Disease Control | 1 | 2020 | 856 | 0.110 |
Why?
|
Keratinocytes | 1 | 2018 | 863 | 0.110 |
Why?
|
Sarcoidosis | 1 | 2019 | 532 | 0.110 |
Why?
|
Perception | 2 | 2019 | 1205 | 0.100 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2019 | 712 | 0.100 |
Why?
|
Incidence | 4 | 2024 | 21480 | 0.100 |
Why?
|
Monocytes | 1 | 2022 | 2595 | 0.100 |
Why?
|
Intestinal Mucosa | 2 | 2021 | 3046 | 0.100 |
Why?
|
Neurodegenerative Diseases | 1 | 2022 | 1087 | 0.100 |
Why?
|
Gastrointestinal Diseases | 1 | 2021 | 1203 | 0.100 |
Why?
|
Carcinoma, Basal Cell | 1 | 2018 | 566 | 0.100 |
Why?
|
Abdominal Pain | 1 | 2019 | 1069 | 0.100 |
Why?
|
Radiography, Thoracic | 1 | 2019 | 1315 | 0.100 |
Why?
|
Pandemics | 3 | 2020 | 8703 | 0.100 |
Why?
|
Endothelial Growth Factors | 1 | 2014 | 680 | 0.100 |
Why?
|
Disease-Free Survival | 2 | 2019 | 6832 | 0.100 |
Why?
|
Fatigue | 1 | 2019 | 1549 | 0.090 |
Why?
|
Medical Oncology | 2 | 2022 | 2339 | 0.090 |
Why?
|
Education, Medical, Undergraduate | 1 | 2020 | 1085 | 0.090 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2021 | 2054 | 0.090 |
Why?
|
Surgical Procedures, Operative | 1 | 2022 | 1941 | 0.090 |
Why?
|
Attitude | 1 | 2015 | 770 | 0.090 |
Why?
|
Age Distribution | 1 | 2016 | 2858 | 0.090 |
Why?
|
Health Personnel | 1 | 2024 | 3390 | 0.090 |
Why?
|
Sex Factors | 2 | 2021 | 10603 | 0.080 |
Why?
|
Syndrome | 1 | 2015 | 3271 | 0.080 |
Why?
|
Palliative Care | 2 | 2023 | 3645 | 0.080 |
Why?
|
Risk Factors | 6 | 2024 | 74840 | 0.080 |
Why?
|
Time Factors | 2 | 2021 | 40065 | 0.080 |
Why?
|
Tomography, X-Ray Computed | 2 | 2024 | 20659 | 0.080 |
Why?
|
Severity of Illness Index | 3 | 2020 | 15880 | 0.070 |
Why?
|
Diet, Fat-Restricted | 1 | 2010 | 328 | 0.070 |
Why?
|
Attitude to Health | 1 | 2016 | 2020 | 0.070 |
Why?
|
Neoplasm Staging | 2 | 2019 | 11206 | 0.070 |
Why?
|
Hematologic Neoplasms | 1 | 2019 | 1927 | 0.070 |
Why?
|
Quality of Life | 3 | 2020 | 13462 | 0.070 |
Why?
|
Medicaid | 1 | 2020 | 2833 | 0.070 |
Why?
|
Cell Differentiation | 1 | 2025 | 11641 | 0.070 |
Why?
|
Blood Pressure Determination | 1 | 2010 | 647 | 0.070 |
Why?
|
Prevalence | 1 | 2023 | 15842 | 0.070 |
Why?
|
Treatment Outcome | 4 | 2021 | 65188 | 0.060 |
Why?
|
Motivation | 1 | 2015 | 2018 | 0.060 |
Why?
|
Odds Ratio | 1 | 2017 | 9649 | 0.060 |
Why?
|
Fruit | 1 | 2010 | 1166 | 0.060 |
Why?
|
Vegetables | 1 | 2010 | 1199 | 0.060 |
Why?
|
Young Adult | 6 | 2020 | 59889 | 0.060 |
Why?
|
Lung | 1 | 2022 | 10033 | 0.050 |
Why?
|
Disease Progression | 1 | 2021 | 13632 | 0.050 |
Why?
|
Child, Preschool | 3 | 2020 | 42500 | 0.050 |
Why?
|
Infant, Newborn | 2 | 2020 | 26346 | 0.050 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2014 | 3513 | 0.050 |
Why?
|
Multivariate Analysis | 1 | 2016 | 12056 | 0.050 |
Why?
|
Blister | 1 | 2023 | 90 | 0.050 |
Why?
|
Viral Load | 2 | 2023 | 3386 | 0.050 |
Why?
|
Dermatitis | 1 | 2024 | 199 | 0.050 |
Why?
|
Pregnancy | 1 | 2024 | 30260 | 0.050 |
Why?
|
Intranuclear Inclusion Bodies | 1 | 2022 | 34 | 0.050 |
Why?
|
Adolescent | 5 | 2020 | 88835 | 0.050 |
Why?
|
Infant | 2 | 2020 | 36386 | 0.050 |
Why?
|
Neoplasm Invasiveness | 2 | 2021 | 3602 | 0.050 |
Why?
|
Emergency Service, Hospital | 1 | 2020 | 7875 | 0.050 |
Why?
|
Biological Therapy | 1 | 2022 | 140 | 0.040 |
Why?
|
Databases, Factual | 1 | 2016 | 8067 | 0.040 |
Why?
|
Child | 4 | 2020 | 80564 | 0.040 |
Why?
|
Mice, Inbred C57BL | 3 | 2025 | 22332 | 0.040 |
Why?
|
United States | 6 | 2021 | 72903 | 0.040 |
Why?
|
Vitiligo | 1 | 2020 | 96 | 0.040 |
Why?
|
Tacrolimus | 1 | 2023 | 753 | 0.040 |
Why?
|
Delphi Technique | 1 | 2023 | 893 | 0.040 |
Why?
|
Italy | 1 | 2021 | 854 | 0.040 |
Why?
|
Follow-Up Studies | 1 | 2020 | 39193 | 0.040 |
Why?
|
New York City | 1 | 2021 | 733 | 0.040 |
Why?
|
Risk | 1 | 2010 | 9591 | 0.040 |
Why?
|
Curriculum | 2 | 2023 | 3782 | 0.040 |
Why?
|
New York | 1 | 2020 | 880 | 0.040 |
Why?
|
Postoperative Period | 1 | 2022 | 1816 | 0.040 |
Why?
|
Interleukin-12 | 1 | 2020 | 579 | 0.040 |
Why?
|
Head | 1 | 2023 | 925 | 0.040 |
Why?
|
Antibody Formation | 1 | 2022 | 1391 | 0.040 |
Why?
|
Pruritus | 1 | 2020 | 378 | 0.030 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2021 | 4642 | 0.030 |
Why?
|
Prospective Studies | 2 | 2022 | 54802 | 0.030 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2021 | 752 | 0.030 |
Why?
|
Hospitalists | 1 | 2020 | 297 | 0.030 |
Why?
|
Interleukin-4 | 1 | 2020 | 1162 | 0.030 |
Why?
|
Cytokines | 2 | 2021 | 7421 | 0.030 |
Why?
|
Advisory Committees | 1 | 2020 | 796 | 0.030 |
Why?
|
Frontal Lobe | 1 | 2022 | 1410 | 0.030 |
Why?
|
Mice | 4 | 2025 | 81819 | 0.030 |
Why?
|
Physician Executives | 1 | 2015 | 140 | 0.030 |
Why?
|
Interdisciplinary Communication | 1 | 2020 | 932 | 0.030 |
Why?
|
Streptavidin | 1 | 2014 | 81 | 0.030 |
Why?
|
Needs Assessment | 1 | 2020 | 1138 | 0.030 |
Why?
|
SEER Program | 1 | 2019 | 1446 | 0.030 |
Why?
|
Tumor Burden | 1 | 2020 | 1885 | 0.030 |
Why?
|
Sirolimus | 1 | 2021 | 1545 | 0.030 |
Why?
|
Kaplan-Meier Estimate | 1 | 2024 | 6499 | 0.030 |
Why?
|
Health Care Surveys | 1 | 2020 | 2424 | 0.030 |
Why?
|
Disease Susceptibility | 1 | 2020 | 1789 | 0.030 |
Why?
|
Attitude of Health Personnel | 2 | 2019 | 3925 | 0.030 |
Why?
|
Biotin | 1 | 2014 | 257 | 0.030 |
Why?
|
Disease Outbreaks | 1 | 2022 | 1759 | 0.030 |
Why?
|
Proto-Oncogene Proteins | 1 | 2025 | 4520 | 0.020 |
Why?
|
Host-Pathogen Interactions | 1 | 2021 | 1461 | 0.020 |
Why?
|
Inflammation Mediators | 1 | 2021 | 1884 | 0.020 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2021 | 2056 | 0.020 |
Why?
|
Antigens, Neoplasm | 1 | 2020 | 2002 | 0.020 |
Why?
|
Antibodies, Neutralizing | 1 | 2022 | 2010 | 0.020 |
Why?
|
Hypoglycemic Agents | 1 | 2024 | 3110 | 0.020 |
Why?
|
Interferon-gamma | 1 | 2020 | 3160 | 0.020 |
Why?
|
Colonoscopy | 1 | 2019 | 1406 | 0.020 |
Why?
|
Risk Reduction Behavior | 1 | 2018 | 1123 | 0.020 |
Why?
|
Leadership | 1 | 2020 | 1392 | 0.020 |
Why?
|
Antibodies, Viral | 1 | 2022 | 3211 | 0.020 |
Why?
|
Vaccination | 1 | 2022 | 3426 | 0.020 |
Why?
|
Hypertension | 1 | 2010 | 8626 | 0.020 |
Why?
|
Animals | 4 | 2025 | 168764 | 0.020 |
Why?
|
Ambulatory Care | 1 | 2020 | 2778 | 0.020 |
Why?
|
Calcium-Binding Proteins | 1 | 2014 | 1077 | 0.020 |
Why?
|
Mice, Knockout | 1 | 2025 | 14448 | 0.020 |
Why?
|
Inpatients | 1 | 2021 | 2564 | 0.020 |
Why?
|
Hematopoietic Stem Cells | 1 | 2021 | 3401 | 0.020 |
Why?
|
Neoplasm Metastasis | 1 | 2019 | 4893 | 0.020 |
Why?
|
Mice, Transgenic | 1 | 2021 | 9550 | 0.020 |
Why?
|
Societies, Medical | 1 | 2020 | 3956 | 0.020 |
Why?
|
Massachusetts | 1 | 2021 | 8875 | 0.020 |
Why?
|
Molecular Targeted Therapy | 1 | 2019 | 2822 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2019 | 8529 | 0.020 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2021 | 3111 | 0.020 |
Why?
|
Cause of Death | 1 | 2018 | 3708 | 0.020 |
Why?
|
Communication | 1 | 2020 | 3916 | 0.020 |
Why?
|
Antibodies | 1 | 2014 | 2417 | 0.020 |
Why?
|
Cell Proliferation | 1 | 2021 | 10429 | 0.020 |
Why?
|
Cells, Cultured | 1 | 2021 | 18973 | 0.020 |
Why?
|
Survival Analysis | 1 | 2018 | 10070 | 0.010 |
Why?
|
Apoptosis | 1 | 2021 | 9514 | 0.010 |
Why?
|
HEK293 Cells | 1 | 2014 | 4260 | 0.010 |
Why?
|
Delivery of Health Care | 1 | 2023 | 5370 | 0.010 |
Why?
|
Early Detection of Cancer | 1 | 2019 | 3236 | 0.010 |
Why?
|
Mass Screening | 1 | 2019 | 5446 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2021 | 22223 | 0.010 |
Why?
|
Telemedicine | 1 | 2020 | 3105 | 0.010 |
Why?
|
Signal Transduction | 1 | 2025 | 23601 | 0.010 |
Why?
|
DNA | 1 | 2014 | 7202 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2014 | 17075 | 0.010 |
Why?
|